Krabeva 400mg

Krabeva 400mg Injection is a medication used to treat various types of cancer, including breast cancer, lung cancer, kidney cancer, and more. Here are some key points about the product:

Composition:

Krabeva 400mg Injection contains Bevacizumab, a recombinant humanized monoclonal antibody that targets vascular endothelial growth factor (VEGF).

Indications:

Krabeva 400mg Injection is indicated for the treatment of:

1. Metastatic breast cancer in combination with chemotherapy
2. Metastatic non-small cell lung cancer (NSCLC) in combination with chemotherapy
3. Metastatic renal cell carcinoma (RCC) in combination with interferon alfa
4. Metastatic cervical cancer in combination with chemotherapy
5. Epithelial ovarian, fallopian tube, or primary peritoneal cancer in combination with chemotherapy

Mechanism of Action:

Bevacizumab works by:

1. Inhibiting the binding of VEGF to its receptors on the surface of endothelial cells, which leads to reduced angiogenesis (the formation of new blood vessels)
2. Reducing the growth and proliferation of cancer cells

Dosage and Administration:

The recommended dosage of Krabeva 400mg Injection is:

• 400mg administered as an intravenous infusion every 2 weeks
• Administered in a healthcare setting under the supervision of a healthcare professional

Side Effects:

Common side effects of Krabeva 400mg Injection include:

1. Hypertension (high blood pressure)
2. Proteinuria (excess protein in the urine)
3. Nausea and vomiting
4. Fatigue
5. Headache
6. Increased risk of infections

Serious side effects can include:

1. Gastrointestinal perforation (a hole in the stomach or intestine)
2. Hemorrhage (bleeding)
3. Arterial thromboembolism (blood clots)
4. Cardiac arrest
5. Neurological events (e.g., stroke, seizures)

Contraindications:

Krabeva 400mg Injection is contraindicated in patients with:

1. Hypersensitivity to Bevacizumab
2. Severe hypertension that is not controlled
3. Severe proteinuria or nephrotic syndrome
4. Active bleeding or a history of gastrointestinal perforation
5. Recent history of arterial thromboembolic events

Precautions:

1. Patients with a history of hypertension or proteinuria should be closely monitored while receiving Krabeva 400mg Injection.
2. Patients with a history of gastrointestinal disorders or bleeding should be closely monitored while receiving Krabeva 400mg Injection.
3. Patients with a history of cardiovascular disease or stroke should be closely monitored while receiving Krabeva 400mg Injection.

Patient Counseling:

• Patients should be counseled on the importance of taking their medication as directed and not missing doses.
• Patients should be instructed to report any signs of hypertension, proteinuria, nausea, or vomiting.
• Patients should be advised to report any changes in their appetite or weight loss.

Storage and Handling:

• Store refrigerated at 2°C to 8°C (36°F to 46°F).
• Do not freeze or expose to direct sunlight.
• Use within 28 days of opening.

Please note that the dosage and administration information is based on the recommended dosage and may vary depending on individual patient needs and circumstances.